Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

Original CPS+EG score

An additive 0-6 post-neoadjuvant prognostic score using AJCC breast 6th-edition stages, ER status, and nuclear grade.

Evidence-based context for fast calculator use

Purpose:
Reproduce the original 2008 CPS+EG score and its source-specific historical outcome row.
Population:
Nonmetastatic breast cancer treated with neoadjuvant cytotoxic chemotherapy followed by surgery.
Factors:
Presenting clinical AJCC 6 stage, Final post-neoadjuvant yp AJCC 6 stage, Diagnostic-biopsy ER status, Diagnostic-biopsy nuclear grade
Reference:
Jeruss et al. 2008, DOI 10.1200/JCO.2007.11.5352; Mittendorf et al. 2011, DOI 10.1200/JCO.2010.31.8469.
HomeCPS+EG Score (Original AJCC 6th-Edition Model)
Pin your most used calculators here by clicking the star in the dropdown.

CPS+EG Score (Original AJCC 6th-Edition Model)

Clinical Context & Background

This calculator implements the original CPS+EG system developed in 2008 and validated in 2011. It requires the AJCC breast 6th-edition presenting clinical anatomic stage before neoadjuvant treatment, the final post-neoadjuvant yp anatomic stage after surgery, and ER status and nuclear grade from the diagnostic biopsy.
It applies to nonmetastatic breast cancer treated with neoadjuvant cytotoxic chemotherapy followed by surgery. Stage IV or M1 disease is not accepted. No field is preselected; all four source categories must be entered explicitly.
The historical outcome rows are derivation-cohort estimates, not individualized predictions. The original and validation cohorts excluded neoadjuvant trastuzumab and predate contemporary HER2-targeted therapy and immunotherapy. Neo-Bioscore is a separate later model and is not calculated here.
Primary Source EvidenceJeruss JS et al. J Clin Oncol. 2008;26:246-252. DOI: 10.1200/JCO.2007.11.5352. Mittendorf EA et al. J Clin Oncol. 2011;29:1956-1962. DOI: 10.1200/JCO.2010.31.8469.
Formula Logic
CPS+EG = AJCC 6th-edition presenting clinical-stage points + post-neoadjuvant yp-stage points + ER-status points + diagnostic-biopsy nuclear-grade points.

Reference Data

CPS+EG Score2008 derivation-cohort 5-Year DMFS2008 derivation-cohort 5-Year DSS
098% (95% CI 88-100)100% (95% CI not reported)
194% (95% CI 88-97)98% (95% CI 94-100)
287% (95% CI 82-91)96% (95% CI 91-98)
379% (95% CI 72-84)88% (95% CI 83-92)
463% (95% CI 54-70)72% (95% CI 64-79)
543% (95% CI 29-56)57% (95% CI 42-70)
622% (95% CI 3-51)22% (95% CI 3-51)

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • After surgery following neoadjuvant cytotoxic chemotherapy for nonmetastatic breast cancer.
  • Use presenting c stage and final yp stage under AJCC breast 6th edition.

How To Interpret

  • Report the exact integer score from 0 through 6.
  • Outcome rows are historical cohort estimates and must not be treated as individualized survival probabilities.

What To Do Next

  • Document the four source inputs and exact score.
  • Interpret prognosis and treatment in contemporary multidisciplinary context.

Limitations

  • Not applicable to M1 disease.
  • Original cohorts excluded neoadjuvant trastuzumab and predate modern HER2-targeted therapy and immunotherapy; Neo-Bioscore is separate.

Validated Population

Nonmetastatic breast cancer treated with neoadjuvant cytotoxic chemotherapy followed by surgery in the original and external validation cohorts.

Source-boundary example

Clinical IIIA contributes 1 point, whereas IIIB contributes 2; final yp IIIB contributes 1, whereas yp IIIC contributes 2.

Calculation verification history

Verified

  1. : Production browser revalidation

    • Three source-backed cases passed through visible production controls at CPS+EG scores 0, 3, and 6.
    • All score labels rendered as expected.
    • No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
    Download latest production check (Excel)

    Case-level evidence is retained in validation/browser-revalidation/breast-cancer-cps-eg-score-2026-08-03.json.

  2. : Production browser validation

    • Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
    • Overall browser status: failed-console. medium: Production emitted minified React error #418 during the route load.
    • Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.

    Case-level production evidence is retained in validation/browser-production/breast-cancer-cps-eg-score.json.

  3. : Full validation test

    • 672/672 exhaustive source-state, malformed-input, semantic UI, reset, trace, source-row, registry, report, history, and isolation checks passed.
    • This verifies implementation against the cited original CPS+EG model; it is not independent clinical validation, regulatory approval, or medical advice.

  4. : Calculation and input-contract correction

    • Restored semantic AJCC breast 6th-edition presenting clinical and final post-neoadjuvant yp stage categories instead of pre-scored options.
    • Required all four source inputs, removed silent defaults and coercion, and preserved the exact 0-6 score without invented low/intermediate/high bands.
    • Restored all seven derivation-cohort DMFS and DSS rows with published confidence intervals and prominent contemporary-treatment limitations.

    Included in the current validation report.

Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.

Found a possible issue? Report it to improve this calculator

Share This Calculator

Share:

Related Tools

Residual Cancer Burden (RCB)

Frequently Asked Questions

When should CPS+EG Score (Original AJCC 6th-Edition Model) be used?

Use it for patients undergoing breast cancer risk, staging, pathology, recurrence, or treatment-benefit assessment when all required inputs and the intended clinical setting are confirmed.

Can CPS+EG Score (Original AJCC 6th-Edition Model) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.